Johnson & Johnson (JNJ) - Moat Analysis

Business Model

25%

4.1/5

4.14

Post-Kenvue, Johnson & Johnson runs a two-segment healthcare portfolio (Innovative Medicine 64.1% and MedTech 35.9% of FY2025 revenue) selling chronic, largely non-discretionary products globally. Revenue grew every year across FY2021-FY2025 including through COVID and the 2025 Stelara loss of exclusivity. Concentration within a single healthcare sector and U.S.-heavy geographic mix cap the model's upside.

Sub-dimension

Summary

Score

Revenue Predictability30%

4.00

Forward visibility of revenue: backlog, contracts, retention

4.00

Summary

Prescription-driven demand and long-cycle MedTech procedures generate consistent visibility. FY2025 revenue reached $94.2B and FY2026 guidance calls for approximately $100.5B, extending a multi-decade revenue growth record through COVID and through the 2025 Stelara loss of exclusivity, though periodic franchise-level LOE volatility remains.

4.00

Product Diversification10%

4.00

Diversification across product lines, segments, and customers

4.00

Summary

Two segments (Innovative Medicine 64.1%, MedTech 35.9% of FY2025 revenue) across oncology, immunology, neuroscience, cardiovascular, surgery, and vision. Darzalex is the largest product at roughly $13B annualized (about 14% of total), no other drug exceeds 10%, and both segments sit within a single healthcare sector.

4.00

Geographic Diversification15%

3.00

Distribution across regions and home-market dependence

3.00

Summary

FY2024 revenue mix was approximately 56.6% United States and 43.4% international, with meaningful exposure across Europe, Asia Pacific, and Latin America. Home-country revenue above half of the total means U.S. healthcare policy shifts (CMS drug-price negotiation, tariffs) carry outsized weight.

3.00

Scalability20%

3.25

Ability to grow revenue without proportional cost increases

3.25

Summary

Innovative Medicine carries strong gross margins and operating leverage on incremental prescription volume, while MedTech runs asset-heavier with manufacturing and sales-force intensity. Company-wide adjusted operating margins run in the high-20s to low-30s range across FY2021-FY2025, above average for diversified healthcare but structurally below software-like economics.

3.25

Revenue Quality25%

4.25

Nature of the revenue: contractual vs transactional, defensive vs discretionary

4.25

Summary

Branded pharmaceuticals like Darzalex, Tremfya, and Carvykti are prescribed for chronic or multi-cycle diseases, generating multi-year per-patient revenue streams. MedTech devices carry multi-year installed-base economics. Revenue grew every fiscal year across FY2021-FY2025 including through the Stelara LOE, and FY2026 free cash flow is guided to approximately $21B.

4.25

Competitive Advantages

40%

3.0/5

2.98

Branded-drug pricing power, FDA approval barriers, and a broad patent portfolio provide a real regulatory moat, but biosimilars systematically erode franchises at patent cliff. There is no network effect in pharmaceuticals, the consumer brand left with the 2023 Kenvue spin, and innovation scale is comparable to peers like Merck, Pfizer, and Eli Lilly rather than uniquely dominant.

Sub-dimension

Summary

Score

Pricing Power30%

3.25

The company's ability to raise prices without losing customers

3.25

Summary

3.25

Switching Costs20%

3.50

How costly it is for customers to switch to a competitor

3.50

Summary

3.50

Network Effects20%

1.50

Whether the product becomes more valuable as more users join

1.50

Summary

1.50

Brand Strength15%

3.00

Degree to which brand drives premium pricing and loyalty

3.00

Summary

3.00

Innovation Barrier15%

3.75

How difficult it is for competitors to replicate the core technology

3.75

Summary

3.75

Full analysis requires login